A flavanone 3-hydroxylase mutant and its genetically engineered bacteria and application

By mutation and genetically engineering the flavanone-3-hydroxylase, the problems of intermediate volume accumulation and low yield were solved, and efficient production of dihydroquercetin was achieved, reducing production costs and increasing output by 1.67 times.

CN117925550BActive Publication Date: 2024-11-29SOUTH CHINA UNIV OF TECH

Patent Information

Application Number
CN202410027629.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-09
Publication Date
2024-11-29
Estimated Expiration
2044-01-09

AI Technical Summary

Technical Problem

In the biosynthesis of dihydroquercetin, a common challenge is the simultaneous accumulation of intermediates, especially sago and dihydro-sankaol, resulting in the efficiency of the rate-limiting enzyme flavanone-3-hydroxylase (F3H) Low, affecting output and cost.

Method used

By modifying the flavanone-3-hydroxylase from apple-derived flavanone-3-hydroxylase mutant MdF3HP221A, the mutant proline is alanine, and combined with the recombinant expression plasmid and genetically engineered strain, it is optimized The catalytic efficiency and properties of enzymes are used to efficiently produce dihydroquercetin in Saccharomyces cerevisiae.

Benefits of technology

The yield of dihydroquercetin has been significantly improved, the accumulation of by-products has been reduced, and the production cost has been reduced. The yield of dihydroquercetin in mutants reaches 1.67 times that of wild-type enzymes under fermentation conditions, and has good application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117925550B_ABST
    Figure CN117925550B_ABST
Patent Text Reader

Abstract

The present invention discloses a flavanone 3-hydroxylase mutant and its genetic engineering bacteria and application, belonging to the field of genetic engineering and enzymology research. The flavanone 3-hydroxylase mutant is obtained by a single mutation of the 221st position of the flavanone 3-hydroxylase amino acid sequence to alanine, and the amino acid sequence is shown in SEQ ID NO.5. The present invention also provides a gene encoding the mutant and a recombinant engineering strain containing the gene; the mutant can increase the yield of dihydroquercetin, and the product content is 1.67 times that of the wild-type enzyme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a flavanone 3-hydroxylase mutant and a genetic engineering bacterium and application thereof, belonging to the technical field of genetic engineering and enzyme engineering. Background Art

[0002] Dihydroquercetin, also known as tachyphyllin (DHQ), is a biologically active flavonoid compound. Due to its antioxidant, antiviral and anticancer biological activities, DHQ has become an important dietary supplement and functional food, showing potential therapeutic value in the prevention and treatment of various diseases such as neurodegenerative diseases, hypertension and viral infections. The transformation and optimization of cell factories using technologies such as genetic engineering and enzyme engineering has become an effective method for the efficient and sustainable production of such valuable natural products. Its advantages include short production cycle, high production intensity, and no seasonal restrictions. Saccharomyces cerevisiae has achieved remarkable success in the biosynthesis of various flavonoids, including anthocyanins, scutellarin, catechins and kaempferol.

[0003] Flavanone-3-hydroxylase (F3H) is a member of the 2-oxoglutarate-dependent dioxygenase family and plays an important role in the biosynthesis pathway of flavonoids. Its main function is to catalyze the hydroxylation of the third position of the C ring of naringenin (NAR) or eriodictyol (ERI) to form dihydrokaempferol (DHK) and DHQ, respectively. However, a common challenge in the synthesis of DHQ is the simultaneous accumulation of multiple intermediates, especially ERI and DHK, so F3H is considered to be the rate-limiting enzyme in the hydroxylation process of DHQ. An effective way to overcome this challenge is to optimize the properties of the enzyme through protein engineering, including directed evolution, rational design, computer-aided design, and machine learning-based design. These methods can improve the catalytic efficiency, thermal stability, substrate selectivity, and pH adaptability of the enzyme, which is of great industrial significance for effectively promoting the synthesis of flavonoids. Summary of the invention

[0004] The primary purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a flavanone 3-hydroxylase mutant.

[0005] The second object of the present invention is to provide a nucleic acid molecule encoding the above-mentioned flavanone 3-hydroxylase mutant.

[0006] The third object of the present invention is to provide a recombinant expression plasmid.

[0007] The fourth object of the present invention is to provide a genetically engineered bacterium.

[0008] The fifth object of the present invention is to provide the use of the flavanone 3-hydroxylase mutant or the genetically engineered bacteria in the preparation of dihydroquercetin.

[0009] The purpose of the present invention is achieved through the following technical solutions:

[0010] A flavanone 3-hydroxylase mutant is obtained by mutation of flavanone 3-hydroxylase (MdF3H), and its amino acid sequence is shown in SEQ ID NO.5. The mutant is named MdF3H in the present invention. P221A .

[0011] The flavanone 3-hydroxylase is derived from apple (Malus domestica), and its amino acid sequence is shown in SEQ ID NO.1, and its encoding nucleotide sequence is shown in SEQ ID NO.2.

[0012] The mutation is to mutate the proline at position 221 of the amino acid sequence shown in SEQ ID NO.1 into alanine.

[0013] The sequence of the nucleic acid molecule encoding the flavanone 3-hydroxylase mutant is preferably as shown in SEQ ID NO.6.

[0014] A recombinant expression plasmid contains the above nucleic acid molecule.

[0015] The recombinant expression plasmid also contains at least one of a flavonoid 3'-hydroxylase gene (GhF3'H) and a cytochrome P450 reductase gene (SmCPR).

[0016] The flavonoid 3'-hydroxylase is derived from Gerbera hybrid; the sequence of the flavonoid 3'-hydroxylase gene is shown in SEQ ID NO.3.

[0017] The cytochrome P450 reductase is derived from Silybum marianum; the sequence of the cytochrome P450 reductase gene is shown in SEQ ID NO.4.

[0018] The backbone of the recombinant expression plasmid is preferably derived from p416GPD.

[0019] A genetically engineered bacterium contains the above nucleic acid molecule or the above recombinant expression plasmid.

[0020] The genetically engineered bacteria are obtained by transferring the above-mentioned recombinant expression plasmid into the starting strain.

[0021] The starting strain is Saccharomyces cerevisiae.

[0022] The Saccharomyces cerevisiae is a CEN.PK background strain; more preferably, the Saccharomyces cerevisiae is strain IMX581.

[0023] The use of the above genetically engineered bacteria in the preparation of dihydroquercetin preferably comprises the following steps:

[0024] (1) inoculating the genetically engineered bacteria into a fermentation medium for cultivation;

[0025] (2) Then, the substrate is added and the culture is continued, and the fermentation product is collected to obtain dihydroquercetin.

[0026] The fermentation medium described in step (1) is preferably YPD liquid medium or SC-Ura liquid medium.

[0027] The culture conditions in step (1) are preferably cultured at 28-32° C. and 150-250 rpm for 10-30 h; more preferably cultured at 30° C. and 220 rpm for 16-24 h.

[0028] The substrate in step (2) is preferably at least one of eriodictyol and naringenin.

[0029] The added amount of eriodictyol is preferably 100-300 mg / L, and more preferably 200 mg / L.

[0030] The added amount of naringenin is preferably 700-900 mg / L, and more preferably 800 mg / L.

[0031] The culture conditions of step (2) are preferably 28-32° C., 150-250 rpm, 80-180 h; more preferably, fermentation is performed at 30° C., 220 rpm, 96-168 h.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] (1) The present invention constructs a flavanone 3-hydroxylase mutant by modifying the flavanone 3-hydroxylase from apple (Malus domestica) for producing dihydroquercetin.

[0034] (2) The mutant constructed by the present invention greatly increases the yield of dihydroquercetin, while reducing the accumulation of by-products, effectively reducing the production cost.

[0035] (3) The mutant obtained by the present invention can produce 516.84 mg / L of dihydroquercetin in a 20 mL fermentation system with 800 mg / L naringenin as a substrate after fermentation for 168 h, which is 1.67 times that of the wild-type enzyme and has good application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The figure shows the plasmid map of p416-MdF3H and the gel electrophoresis diagram of the restriction enzyme cutting bands.

[0037] Figure 2 The result graph shows the improvement of the conversion rate of eriodictyol to dihydroquercetin in the heterologous expression MdF3H mutant strain.

[0038] Figure 3 Schematic diagram of the biosynthesis pathway of dihydroquercetin from naringenin in Saccharomyces cerevisiae.

[0039] Figure 4 The map is for plasmids p416-DHQ and p416-DHQM.

[0040] Figure 5 This is a diagram showing the fermentation results of the recombinant strain containing the mutant plasmid in a shake flask using 200 mg / L naringenin to synthesize dihydroquercetin.

[0041] Figure 6 Shows the background spectrum of each strain.

[0042] Figure 7 This is a diagram showing the fermentation results of the recombinant strain containing the mutant fragment in a shake flask using 800 mg / L naringenin to synthesize dihydroquercetin. DETAILED DESCRIPTION

[0043] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0044] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources;

[0045] In the present invention, unless otherwise specified, "%" used to describe concentration means weight percentage, and ":" means weight ratio.

[0046] In the present invention, unless otherwise specified, yeast strain transformation adopts yeast chemical transformation method, and the specific operation is referred to the relevant standard specification.

[0047] Gibson connection, specific operations follow the instructions of NEB Gibson Assembly Cloning kit (Cat. No. E2611, NEB).

[0048] Plasmid extraction: The specific operation was carried out according to the instruction manual of HiPure Plasmid Micro Kit (Cat. No. P1001-03, Magen).

[0049] The experimental methods for which specific conditions are not specified in the following examples are generally carried out according to conventional conditions, such as those described in "Molecular Cloning Experiment Guide" (Beijing: Science Press, 2017) and "Yeast Genetics Methods Experiment Guide" (Beijing: Science Press, 2016).

[0050] The CRISPR technology used in the following examples is disclosed in the prior art (FEMS Yeast Research, 2015, 15(2): fov004.). In addition, the plasmid p416GPD used in the following examples has been disclosed in the document "Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene 1995, 156: 119-122."; the plasmid pROS10 has been disclosed in the document "CRISPR / Cas9: amolecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. FEMS Yeast Research, 2015, 15, fov004", and can be obtained from EUROSCARF.

[0051] In order to better understand the content of the present invention, the strain IMX581 (available from EUROSCARF) with the CEN.PK background of Saccharomyces cerevisiae is used as the starting strain for further explanation of the specific examples.

[0052] In the present invention, the dihydroquercetin yield converted by strain fermentation is detected by the following method:

[0053] After the fermentation, the cells were collected and the content of dihydroquercetin was detected by HPLC.

[0054] Extraction of dihydroquercetin: Take 500 μL of fermentation broth, add an equal volume of methanol, shake for 5 minutes, centrifuge at 13000 rpm for 5 minutes, and filter through a 0.22 μm nylon membrane in a liquid phase injection bottle for use. HPLC detection method: Thermo Fisher (Hypers11 ODS250×4.6mm, 5μm) C18 column; PDA detector detection, wavelength: 290nm; Chromatographic conditions: gradient elution, phase A is ultrapure water (0.1% v / v trifluoroacetic acid), phase B is acetonitrile (0.1% v / v trifluoroacetic acid); 0-10min, phase B 10-40% v / v; 10-20min, phase B 40-60% v / v; 20-22min, phase B 60-10% v / v; 22-25min, phase B 10% v / v. Flow rate: 1mL / min, column temperature 40℃.

[0055] The present invention relates to the following culture medium:

[0056] LB / Amp liquid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L NaCl, sterilize and cool to about 50°C, add 100 μg / mL ampicillin (filter sterilize).

[0057] SC-Ura liquid culture medium: 0.77 g / L CSM-Ura, 6.7 g / L YNB (without amino acids and ammonium sulfate), 5 g / L (NH4)2SO4, 20 g / L glucose.

[0058] YPD liquid medium: 20 g / L peptone, 10 g / L yeast powder, 20 g / L glucose.

[0059] 5-FOA deplasmid medium: 0.77 g / L CSM-Ura, 6.7 g / L YNB (without amino acids and ammonium sulfate), 5 g / L (NH4)2SO4, 1 g / L 5-FOA, 20 mg / L Ura, 20 g / L glucose.

[0060] For solid culture medium, 20 g / L agar powder is added to the corresponding liquid culture medium.

[0061] Example 1: Acquisition of the MdF3H gene sequence encoding flavanone 3-hydroxylase

[0062] The target gene MdF3H (CAA49353.1) was found on NCBI, and after codon optimization and synthesis at Nanjing GenScript Biotechnology Co., Ltd., plasmid pUC57-MdF3H was obtained. The optimized nucleic acid sequence of MdF3H is shown in SEQ ID NO.2. The synthetic plasmid pUC57-MdF3H was used as a template, and the coding gene of MdF3H was amplified by PCR using the following primers. The primers shown in Table 1 were designed and sent to Shanghai Sangon Biotechnology Co., Ltd. for synthesis. The PCR system and conditions are shown in Tables 2 and 3.

[0063] Table 1 Primer sequences

[0064]

[0065] Table 2 PCR reaction system

[0066]

[0067] Table 3 PCR conditions

[0068]

[0069] Example 2 Construction and heterologous expression of MdF3H mutant

[0070] 1. Construction of MdF3H expression vector

[0071] The vector p416GPD was digested with restriction endonucleases SacI and BamHI at 37°C for 0.5 h. The digestion system is shown in Table 4. The desired fragments were cut out by 0.8% agarose gel electrophoresis and recovered using a gel recovery kit (Magen).

[0072] Table 4 Vector p416GPD restriction enzyme system

[0073]

[0074] Pick a single clone of Saccharomyces cerevisiae IMX581 and add it to 25 μL NaOH solution (20 mM), and treat it at 99°C for 15 min to allow the genome to permeate out of the cell. Using the IMX581 lysate as a template, the primer pairs A1F / A1R and A3F / A3R (see Table 5) were used to PCR amplify the promoter PDC1p and the terminator PGK1t, respectively, and the PCR products were recovered by agarose gel electrophoresis and gel excision. The recovered PDC1p, MdF3H and PGK1t were fused PCR using primer pairs A1F / A3R to obtain PGK1t-MdF3H-PDC1p linear fragments, and the PCR products were recovered by agarose gel electrophoresis and gel excision.

[0075] The recovered PGK1t-MdF3H-PDC1p linear fragment and the p416GPD enzyme digestion recovery fragment were used for plasmid construction using a seamless ligation kit (2X MultiF Seamless Assembly Mix, Ibotek Biotechnology Co., Ltd.). The ligation system is shown in Table 6. The prepared ligation solution was incubated at 50°C for 20 minutes. Transformed into Escherichia coli DH5α competent cells (Beijing Qingke Biotechnology Co., Ltd.). The transformation steps are as follows:

[0076] a) Add 50 μL of competent cells to the ligation solution and place on ice for 5 min.

[0077] b) Incubate in 42℃ water bath for 45s, then place on ice for 2min.

[0078] c) Spread on LB plates containing ampicillin and culture at 37°C overnight for screening.

[0079] On the second day, a single clone was picked and inoculated into 3 mL of LB liquid culture medium with ampicillin and cultured at 37°C / 220 rpm for 16 h. The plasmid was extracted using a plasmid extraction kit (Magen) to obtain plasmid p416-MdF3H. The plasmid was identified using double restriction enzymes SacI and BamHI. The results are as follows: Figure 1 shown.

[0080] Table 5 Primer sequences

[0081]

[0082] Table 6 Gibson connection system

[0083]

[0084] 2. Construction of expression vector containing MdF3H mutant

[0085] Molecular docking: The protein structure of MdF3H (Q06942) was predicted by the AlphaFoldDB module of the Uniprot database. The molecular model of MdF3H enzyme was used as the receptor, and eriodictyol (ERI) and 2OG substrate were used as ligands. Molecular docking was performed using AutodockVina. The binding site Pro221 was found by arranging the order according to the lower the binding energy, the greater the probability.

[0086] Point mutation primers were designed (see Table 5), and the amino acid base at the Pro221 position was mutated to Ala by the designed primers. The p416-MdF3H plasmid was used as a template, and the primer pairs P221AF / A4RD and A4FD / P221AR were used to amplify MdF3H by PCR. P221AThe mutant fragments A and B, PCR system and conditions are shown in Tables 2 and 3, and the extension time is 40s. The PCR products were recovered by agarose gel electrophoresis and gel cutting. Then, the primer pair A4FD / A4RD was used to splice the mutant fragments A and B by fusion PCR to obtain MdF3H P221A , the fusion PCR system and conditions are shown in Table 7 and Table 3, the extension time is 1 min, and the molar ratio of mutant fragments A and B is 1:1. Using the p416-MdF3H plasmid as a template, primers A1R / A3FPCR were used to amplify the p416GPD-PDC1p-PGK1t framework. The PCR system and conditions are shown in Table 2 and Table 3, and the extension time is 2 min. Take 1 μL of PCR product and detect it by 0.8% agarose gel electrophoresis. Add 1 μL of DpnI enzyme to the remaining PCR liquid to digest the methylated template in the PCR product, mix well, incubate at 37°C for 3 hours, and then recover the PCR product by agarose gel electrophoresis and gel cutting. The recovered MdF3H P221A The linear fragment and the p416GPD-PDC1p-PGK1t framework recovery fragment were constructed by seamless connection kit (Ibotek Biotechnology Co., Ltd.-2XMultiF SeamlessAssembly Mix). The plasmid was then transformed into Escherichia coli DH5α competent cells, evenly spread on LB solid medium containing 100 μg / mL ampicillin, cultured at 37°C overnight, and single colonies were picked to LB liquid medium containing 100 μg / mL ampicillin, cultured at 37°C and 220 rpm overnight, and the plasmid was extracted with a plasmid extraction kit (Magen) to obtain plasmid p416-MdF3H P221A The obtained mutant plasmid was used as a PCR template, and the primer pair A4FD / A4RD was used to amplify the mutant fragment by PCR, which was sent to Shanghai Sangon Biotech Co., Ltd. for sequencing to confirm that the point mutation plasmid was successfully constructed. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 1 min.

[0087] Table 7 Fusion PCR reaction system

[0088]

[0089] 3. Heterologous expression of MdF3H mutant

[0090] Plasmids p416-MdF3H and p416-MdF3H P221A The yeast chemical transformation method was used to transform into the Saccharomyces cerevisiae IMX581 strain. The specific transformation method is as follows:

[0091] a) Take 50 μL of competent cells, centrifuge (1 min, 5000 rpm) and discard the supernatant.

[0092] b) Add the compounds in Table 8 in order and mix well.

[0093] c) Incubate at 30°C for 30 min and in a 42°C water bath for 40 min.

[0094] d) Spread on SC-Ura solid plate.

[0095] e) Incubate the culture at 30°C for 2 days and recover transformants.

[0096] Table 8 Yeast transformation mixed system

[0097]

[0098] The transformants were transferred to SC-Ura plates and inverted at 30°C for 2 days. Single clones were picked and broken in 25 μL NaOH (20 mM) solution. The designed primer pair A4FD / A4RD matching the upstream and downstream of MdF3H was used to confirm the plasmids p416-MdF3H and p416-MdF3H by PCR with the above NaOH solution as a template. P221A The recombinant Saccharomyces cerevisiae strains were named I0 and P221A.

[0099] Five single colonies of strains I0 and P221A were picked, and each single colony was inoculated into a test tube containing 2.5 mL SC-Ura liquid medium, and cultured at 30°C and 220 rpm for 24 h; the inoculum was transferred to 2.5 mL SC-Ura liquid medium at a 1% v / v inoculum, 200 mg / L ERI substrate was added, and the culture was fermented at 30°C and 220 rpm for 96 h. The cells were collected and the content of dihydroquercetin was detected. Figure 2 .

[0100] Example 3 Construction of recombinant strains containing mutant plasmids

[0101] 1. Construction of a recombinant plasmid strain containing the pathway for synthesizing dihydroquercetin from naringenin

[0102] The target gene flavonoid 3'-hydroxylase gene GhF3'H (ABA64468) and cytochrome P450 SmCPR (Lv Y, Gao S, Xu S, et al. Spatial organization of silybin biosynthesis in milk thistle [Silybum marianum (L.) Gaertn] [J]. Plant Journal, 2017, 92 (6): 995-1004) were found on NCBI, and after codon optimization and synthesis at Nanjing GenScript Biotechnology Co., Ltd., synthetic plasmids pUC57-GhF3'H and pUC57-SmCPR were obtained. Among them, the sequence of the encoding nucleic acid of GhF3'H is shown in SEQ ID NO.3; the sequence of the encoding nucleic acid of SmCPR is shown in SEQ ID NO.4.

[0103] The synthetic plasmids pUC57-GhF3'H and pUC57-SmCPR were used as templates to PCR amplify the GhF3'H and SmCPR genes using primer pairs A7F / A7R and A11F / A11R, respectively. The desired fragments were cut out and recovered by 0.8% agarose gel electrophoresis. The primers used are shown in Table 9.

[0104] Table 9 Primer sequences

[0105]

[0106] Using yeast cell lysate (prepared according to the method of Example 2) as a template, the promoter GPDp, TEF1p and the terminator CYC1t, ENO2t were PCR amplified using primer pairs A6FD / A6RD, A10F / A10R, A8F / A8R and A12F / A12R, respectively. After 0.8% agarose gel electrophoresis, the desired fragments were cut out and gel recovered; the recovered GPDp, GhF3'H and CYC1t, TEF1p, SmCPR and ENO2t were subjected to fusion PCR using primer pairs A6FD / A8R and A10F / A12R, respectively, to obtain GPDp-GhF3'H-CYC1t and TEF1p-SmCPR-ENO2t linear fragments, and the PCR products were recovered by agarose gel electrophoresis and gel excision.

[0107] The vector p416GPD was digested with restriction endonucleases SacI and KpnI at 37°C for 2h, and the PCR product was recovered by agarose gel electrophoresis and gel excision. The recovered p416GPD vector framework was used to construct plasmids with PGK1t-MdF3H-PDC1p, GPDp-GhF3'H-CYC1t and TEF1p-SmCPR-ENO2t using a seamless connection kit (2X MultiFSeamless Assembly Mix, Ibotek Biotechnology Co., Ltd.). The plasmid was then transformed into Escherichia coli DH5α competent cells, and the plasmid was extracted with a plasmid extraction kit to obtain plasmid p416-DHQ, which was then digested and sequenced for verification. For specific maps, see Figure 4 .

[0108] The obtained recombinant plasmid p416-DHQ was transformed into the Saccharomyces cerevisiae IMX581 strain by a yeast chemical transformation method, and the transformants were picked and transferred to SC-Ura plates and inverted at 30°C for 2-3 days. Single clones were picked and placed in 25μL NaOH solution (20mM) and treated with cell wall at 99°C for 15min. The designed primer pairs matching the upstream and downstream of the MdF3H and SmCPR genes were used, and the above-mentioned NaOH lysate was used as a template. PCR was used to confirm that the plasmid p416-DHQ had been successfully transformed into the Saccharomyces cerevisiae IMX581 strain to obtain the recombinant strain IDXQM.

[0109] 2. Construction of recombinant strains containing mutant plasmids

[0110] Plasmid p416-MdF3H P221A As a template, PGK1t-MdF3H was obtained by PCR amplification using the A1F / A3R primer pair. P221A -PDC1p linear fragment, and the PCR product was recovered by agarose gel electrophoresis and gel excision. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 2 min. The recovered p416GPD vector framework was combined with PGK1t-MdF3H P221A -PDC1p, GPDp-GhF3'H-CYC1t and TEF1p-SmCPR-ENO2t were constructed by seamless connection kit (2XMultiF Seamless Assembly Mix, Ibotek Biotech Co., Ltd.). The plasmids were then transformed into Escherichia coli DH5α competent cells, and the plasmids were extracted with a plasmid extraction kit (Magen) to obtain plasmid p416-DHQM, which was then digested and sequenced for verification. The specific map is shown in Figure 4 .

[0111] The obtained recombinant plasmid p416-DHQM was transformed into the Saccharomyces cerevisiae IMX581 strain by a yeast chemical transformation method, and the transformants were picked and transferred to SC-Ura plates and inverted at 30°C for 2-3 days. Single clones were picked in 25μL NaOH solution (20mM) and treated with cell wall at 99°C for 15min. Through the designed primer pairs matching the upstream and downstream of the MdF3H and SmCPR genes, the above-mentioned NaOH lysate was used as a template, and PCR was used to confirm that the plasmid p416-DHQM had been successfully transformed into the Saccharomyces cerevisiae IMX581 strain to obtain the recombinant strain 221M.

[0112] 3. Application of recombinant plasmid strains in the production of dihydroquercetin

[0113] Single colonies of the recombinant Saccharomyces cerevisiae strains IDXQM and 221M were picked and inoculated into a test tube containing 2.5 mL of SC-Ura liquid medium and cultured at 30°C and 220 rpm for 24 h; they were transferred to 20 mL of YPD liquid medium at a 1% v / v inoculation volume and fermented at 30°C and 220 rpm for 96 h, and then the cells were collected to detect the content of dihydroquercetin. Figure 5 .

[0114] Example 4 Construction of recombinant strains containing mutant fragments

[0115] In this embodiment, the starting strain of Saccharomyces cerevisiae IMX581 (genotype: MATa ura3-52 can1::cas9-natNT2 TRP1 LEU2 HIS3) is a Cas9 protein expression gene cassette in the CRISPR-Cas9 system integrated into the genome. The starting strain carries a Ura nutrient-deficient screening marker. When genetic operations such as gene integration are performed on the strain, a gRNA expression plasmid (pROS10 (available from EUROSCARF, serial number P30787), with a Ura screening marker) with a 20bp gRNA recognition sequence to target the target gene and its repair fragment can be transformed into the bacteria, and after screening on the corresponding plate, the desired positive transformant can be obtained.

[0116] 1. Construction of pROS10 integration plasmid

[0117] Using pROS10 as a template, PCR amplification was performed using primer pair X-3N20F / X-3N20R to obtain targeting fragment A. The pROS10 vector framework fragment was amplified using primer pair vfP1 and vfP2, and the PCR product was recovered by agarose gel electrophoresis and gel excision. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 30s. The obtained targeting fragment A and vector framework were connected by Gibson ligation technology to construct the pROS10-X-3 plasmid with the gRNA sequence targeting the neutral site of X-3.

[0118] 2. Construction of a recombinant strain containing a pathway for synthesizing dihydroquercetin from naringenin

[0119] Using the recombinant plasmid p416-DHQ as a template, PCR was performed using the primer pair GPGF and X-3ENO2R to obtain a linear fragment of CYC1t-GhF3'H-GPDp-TEF1p-SmCPR-ENO2t containing a 40 bp homology arm downstream of the X-3 position. The PCR product was recovered by agarose gel electrophoresis and gel excision to obtain the repair fragment A. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 3 min.

[0120] Using the recombinant plasmid p416-MdF3H as a template, the primer pair X-3-PDC1F and A5R were used to obtain the linear fragment of PDC1p-MdF3H-PGK1t and containing the homology arm of 40 bp upstream of the X-3 position. The PCR product was recovered by agarose gel electrophoresis and gel excision to obtain the repair fragment B. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 1 min.

[0121] or p416-MdF3H P221A Using primers X-3-PDC1F and A5R as template, PCR was performed to obtain PDC1p-MdF3H containing a 40 bp homology arm upstream of X-3. P221A -PGK1t linear fragment, and the PCR product was recovered by agarose gel electrophoresis and gel excision to obtain repair fragment C. The PCR system and conditions are shown in Tables 2 and 3, and the extension time was 1 min.

[0122] Alternatively, the lysate of the Saccharomyces cerevisiae genome was used as a template, and the primers X-3TDH1pF and TDH1-MdF3HR were used to amplify the promoter TDH1p by PCR. The PCR product was recovered by agarose gel electrophoresis and gel excision. The PCR system and conditions were shown in Tables 2 and 3, and the extension time was 30 s. The plasmid p416-MdF3H P221A Using primers 416-VERCTOR TDH1F and A3R as template, PCR was performed to obtain MdF3H containing the TDH1p promoter homology arm. P221A -PGK1t linear fragment, the PCR product was recovered by agarose gel electrophoresis and gel excision, the PCR system and conditions are shown in Table 2 and Table 3, and the extension time was 1 min. P221A -PGK1t was fused to TDH1p-MdF3H by PCR P221A The PGK1t linear fragment was electrophoresed by agarose gel and the PCR product was recovered by gel excision to obtain the repair fragment D. The fusion PCR system and conditions are shown in Table 7 and Table 3, and the extension time was 2 min.

[0123] The knockout plasmid pROS10-X-3 and the combination of the repair fragment (i.e., A+B or A+C or A+D) were transformed into the Saccharomyces cerevisiae IMX581 strain by the yeast chemical transformation method, spread on SC-Ura solid medium, and cultured at 30°C; the strains were named IDXQ, IDXQ221AP, and IDXQ221AT, respectively. The schematic diagram of the integrated fragment is shown in Figure 6 . After 2 days of culture, the transformants were picked and transferred to SC-Ura plates, inverted and cultured at 30°C for 2 days, and single clones were picked and broken with 25μL NaOH solution, and the strains were identified using VER_X-3F and VER_X-3R primers. The single colonies that were successfully identified were picked and streaked again on 5-FOA plates to remove the plasmid. After 2 days of culture at 30°C, single colonies were re-selected and transferred to SC-URA and YPD plates to confirm that the pROS10-X-3 plasmid was successfully removed. The sequences of all primers used in the above process are shown in Table 10.

[0124] Table 10 Primer sequences

[0125]

[0126] 3. Application of recombinant strains containing mutant fragments in dihydroquercetin

[0127] The recombinant Saccharomyces cerevisiae strains IDXQ, IDXQ221AP and IDXQ221AT were picked and inoculated into a test tube containing 2.5 mL of YPD liquid culture medium and cultured at 30°C and 220 rpm for 16 h; the inoculation amount was transferred to 20 mL of YPD liquid culture medium at 1% v / v, 800 mg / L of naringenin was added as a substrate, and fermented at 30°C and 220 rpm for 168 h, then the cells were collected and the content of dihydroquercetin was detected. The dihydroquercetin production of IDXQ in shake flask fermentation reached a maximum of 309.14 mg / L, the dihydroquercetin production of IDXQ221AP in shake flask fermentation reached a maximum of 477.23 mg / L, and the dihydroquercetin production of IDXQ221AT in shake flask fermentation reached a maximum of 516.84 mg / L. The final dihydroquercetin production results are shown in Figure 7 The results show that the yeast engineered strain containing the MdF3H mutant has a significantly increased dihydroquercetin production. Among them, the strain IDXQ221AT has a production of 516.84 mg / L, which is 1.67 times that of the control strain IDXQ. This indicates that the yeast engineered strain constructed by the present invention can produce a high amount of dihydroquercetin and has good application potential.

[0128] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A flavanone 3-hydroxylase mutant, characterized in that: The amino acid sequence of the flavanone 3-hydroxylase mutant is shown in SEQ ID NO.

5.

2. A nucleic acid molecule encoding the flavanone 3-hydroxylase mutant according to claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that: The sequence of the nucleic acid molecule is shown as SEQ ID NO.

6.

4. A recombinant expression plasmid, characterized in that: Containing the nucleic acid molecule according to claim 2 or 3.

5. The recombinant expression plasmid according to claim 4, characterized in that: The invention also contains at least one of a flavonoid 3'-hydroxylase gene and a cytochrome P450 reductase gene.

6. The recombinant expression plasmid according to claim 5, characterized in that: The sequence of the flavonoid 3'-hydroxylase gene is shown in SEQ ID NO.3; The sequence of the cytochrome P450 reductase gene is shown in SEQ ID NO.

4.

7. A genetically engineered bacterium, characterized in that: Containing the nucleic acid molecule according to claim 2 or 3, or the recombinant expression plasmid according to any one of claims 4 to 6.

8. Use of the genetically engineered bacteria according to claim 7 in the preparation of dihydroquercetin.

9. The use according to claim 8, characterized in that The steps include: (1) inoculating the genetically engineered bacteria according to claim 7 into a fermentation medium for cultivation; (2) Then, the substrate is added and the culture is continued, and the fermentation product is collected to obtain dihydroquercetin.

Citation Information

Patent Citations

  • MF3H mutant as well as related products and application thereof

    CN115058399A

  • Method for Preparing Astragalin from Naringenin Using Microorganism Mutants

    KR1020140125209A

  • Production of Anthocyanin from Simple Sugars

    US20180371513A1

Cited By

  • Recombinant saccharomyces cerevisiae strain for producing gastrodin or p-hydroxybenzyl alcohol as well as construction method and application of recombinant saccharomyces cerevisiae strain

    CN122405458A